Trials / Terminated
TerminatedNCT00338091
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Southern Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely improve the long-term renal outcome in nondiabetic patients with proteinuria and chronic renal insufficiency. The second aim was to compare the long-term renal protection between benazepril and losartan at similar clinical setting.
Conditions
- Renal Insufficiency,Chronic
- Disease Progression
- Proteinuria
- Dose-Response Relationship,Drug
- ACE Inhibitor
- Angiotensin II Type 1 Receptor Blockers
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Benazepril | |
| DRUG | Losartan |
Timeline
- Start date
- 2002-01-01
- Completion
- 2006-05-01
- First posted
- 2006-06-20
- Last updated
- 2006-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00338091. Inclusion in this directory is not an endorsement.